Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under t...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c6fde9992f154241970ca9e958d79a30 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under the biosimilar classification by the EMA. Rather, lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim.Read the original article. |
|---|